The global D-dimer testing market size was USD 1.30 Bn in 2022 and is likely to reach USD 1.85 Bn by 2031, expanding at a CAGR of 4.60% during 2023–2031. The market growth is attributed to the rising demand for advanced point-of-care testing, and increased incidence rate of respiratory and cardiovascular diseases.
D-dimer, also known as fibrin degradation fragment, is a protein fragment that occurs in the bloodstream when fibrinolysis takes place for the breakdown of a blood clot formed when injured.
During the process of fibrinolysis, the clumps present in the blood get broken down; after completion of degradation, the number of clots remains in the blood known as D-dimers. Medical professionals used to carry out elevated d dimer testing by extracting blood samples by using needles to take specimens for further examination to identify the existence of serious blood clots.
D-dimer test is performed when symptoms of blood clotting disorder occurred such as leg pain & swelling, shortness of breathing, nasal congestion, chest pain, and rise in heartbeat, this test is used for diagnosis of various thrombotic disorders such as deep vein thrombosis (DVT) in which clot floats in a deep vein of lower legs followed by other organs of the body.
Pulmonary embolism (PE) is occurred due to obstruction of arteries in the respiratory system and disseminated intravascular coagulation (DIC). As a result, some severe conditions involve the formation of blood clots to a large extent, which can cause organ failure and stroke, due to the obstruction of blood flow to the central nervous system.
The test utilizes monoclonal antibodies of latex particles incorporated in elevated D dimer that increase the molecular weight of the immunocomplexes of the test specimen. The changes observed in the turbidity of the specimen are examined by photometrical analyzers and turbidimetric analyzers.
The market report finds that the COVID-19 pandemic has positively impacted the growth of the global market. The outbreak of the COVID-19 pandemic is creating opportunities for the expansion of the D-dimers market, due to the rising demand of advance diagnostic tools and testing kits.
D Dimer Testing Market Dynamics
The global D-dimer testing market report has up-to-date insights that help in formulating a strategic roadmap about the estimated market scenario and performance during 2023 to 2031.
Drivers
The increasing prevalence of pathophysiological conditions such as various cardiovascular disorders, acute pulmonary syndromes, arterial or venous thromboembolism, cardiac arrhythmias, and acute pancreatitis is a key driver for the rising demand for testing. Moreover, rising demand for advanced point-of-care testing due to lessening the time of treatment and reducing the time of patient stay in the hospital is projected to propel the market growth in the upcoming years. The rising number of geriatric populations who are exposed to severe health risks is expected to boost the market.
Restraints
The presence of heterophilic antibodies prevents the accurate test results of D-dimer testing in the clinical intervention of cardiovascular and pulmonary diseases. This is projected to hinder the market growth in the upcoming years.
Opportunities
The development of aptamers, peptides that bind to a target receptor, lessens the use of antibodies in elevated D dimer testing. These aptamers are offering a higher shelf life of monoclonal antibodies, which can offer profitable opportunities for the market growth.
Scope of D Dimer Testing Market Report
The global D-dimer testing market research report includes an assessment of the market trends, market segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
D-dimer Testing Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2020–2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Product (Analyzers and Reagents & Consumables), Test Type (Clinical Laboratory Tests and Point-of-care Tests), Testing Method (Enzyme-linked Immunosorbent Assays, Latex-enhanced Immunoturbidimetric Assays, Fluorescence Immunoassays, and Others), Application (Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation, and Others), and End-user (Hospitals, Academic & Research Institutes, Diagnostic Centers, and Others),
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, D Dimer Testing Market Size and Analysis, Competitive Landscape, Growth Factors, Market Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
F. Hoffmann-La Roche Ltd; Abbott.; Siemens Healthcare GmbH; Bio-Rad Laboratories, Inc.; Laboratory Corporation of America® Holdings.; ARUP Laboratories.; Diazyme Laboratories, Inc.; BIOMÉRIEUX; Sekisui Diagnostics; BioMedica Diagnostics; BD.; Helena Laboratories; and Quidel Corporation.
|
D Dimer Testing Market Segment Insights
Based on product, the D-dimer testing market is bifurcated into analyzers and reagents & consumables. The reagents & consumables segment is expected to expand at a significant growth rate during the projection period. The increased selling of reagents and testing kits, the wide accessibility of extemporaneous reagents, and the emergence of highly sophisticated robotic D-dimer assay are the key factors that are expected to expand the segment during the forecast period.
The analyzers segment is anticipated to expand at a rapid pace during the forecast period, owing to a reduction in laboratory time along with increasing clinical research that is expected to augmentation of market growth.
On the basis of test type, the market is classified into clinical laboratory tests and point-of-care tests. The clinical laboratory tests segment is anticipated to constitute a dominant share of the market in the coming years, due to the emergence of highly sophisticated D-dimer assays employed for the diagnosis of disseminated intravascular coagulation.
The point-of-care tests segment is estimated to exhibit robust growth during the forecast period, owing to the introduction of various automated methods. The growth of the segment is attributed to excellent design, improved patient care, lesser maintenance charges, reduced risk of errors, and lesser time of diagnosis. The constant efforts of Research & development to develop fast pace point-of-care tests are estimated to boost the segment growth.
Based on testing method, the D-dimer testing market is classified into enzyme-linked immunosorbent assay (ELISA), latex-enhanced immunoturbidimetric assays, fluorescence immunoassays, and others. The ELISA segment is expected to register a robust growth rate during the forecast period, owing to its high sensitivity towards coagulation biological factors. The emerging automated ELISA assays such as the VIDAS method are expected to propel the segment growth.
The fluorescence immunoassay segment is anticipated to register a high CAGR during the forecast period, due to the rising demand for automated fluorescence immunoassay methods for D-dimer testing. These assays provide accurate results due to their higher sensitivity and employed affordable reagents.
On the basis of application, the market is divided into deep vein thrombosis (DVT), pulmonary embolism (PE), disseminated intravascular coagulation (DIC), and others. The deep vein thrombosis segment is expected to register a robust CAGR during the forecast period, due to the increasing incidence of deep vein thrombosis with the risk of complications such as difficulty in diagnosis and hindered movement of hospitalized patients. Patients undergone various surgeries are at higher risk of deep vein thrombosis, which simultaneously increases admittance to hospitals and drug treatment. These are the key factors that propel the segment’s growth in the upcoming years.
Based on end-user, the D-dimer testing market is segmented into hospitals, academic & research institutes, diagnostic centers, and others. The hospital’s segment is accounted for a dominant market share, due to the increasing hospital admittance rate of patients along with enhancement in pulmonary embolism cases across the globe.
The diagnostic center’s segment is expected to register vigorous CAGR during the forecast period, due to low-cost diagnosis and treatment provided by diagnostic centers with enhancement in patient satisfaction.
In terms of region, the global D-dimer testing market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to dominate the market during the projection period, due to wide clinical applications of blood clotting testing stimulated by regulatory bodies that involve in the management of coagulation testing.
The Asia Pacific is expected to grow at a rapid pace during the forecast period, owing to government initiatives for awareness of coagulation tests. These initiatives help medical professionals, which ultimately causes an increased demand for d-dimer tests in the region.
Segments
The global D-dimer testing market has been segmented on the basis of
Products
- Analyzers
- Reagents & Consumables
Test Types
- Clinical Laboratory Tests
- Point-of-care Tests
Testing Methods
- Enzyme-linked Immunosorbent Assays
- Latex-enhanced Immunoturbidimetric Assays
- Fluorescence Immunoassays
- Others
Applications
- Deep Vein Thrombosis
- Pulmonary Embolism
- Disseminated Intravascular Coagulation
- Others
End-users
- Hospitals
- Academic & Research Institutes
- Diagnostic Centers
- Others
Region
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- F. Hoffmann-La Roche Ltd
- Abbott.
- Siemens Healthcare GmbH
- Bio-Rad Laboratories, Inc.
- Laboratory Corporation of America® Holdings.
- ARUP Laboratories.
- Diazyme Laboratories, Inc.
- BIOMÉRIEUX
- Sekisui Diagnostics
- BioMedica Diagnostics
- BD.
- Helena Laboratories
- Quidel Corporation.
Competitive Landscape
Key players competing in the global D-dimer testing market are F. Hoffmann-La Roche Ltd; Abbott.; Siemens Healthcare GmbH; Bio-Rad Laboratories, Inc.; Laboratory Corporation of America® Holdings.; ARUP Laboratories.; Diazyme Laboratories, Inc.; BIOMÉRIEUX; Sekisui Diagnostics; BioMedica Diagnostics; BD.; Helena Laboratories; and Quidel Corporation.
These companies adopted development strategies including mergers, acquisitions, partnerships, collaboration, product launches, and production expansion to expand their consumer base worldwide.
- In April 2019, Diazyme Laboratories introduced its D-dimer assay technique to expand its testing operation.
Request For Customization
Enquiry Before Buying
Speak With Analyst
